NasdaqGM:BLCM

Stock Analysis Report

Executive Summary

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.

Snowflake

Fundamentals

Fair value with limited growth.


Similar Companies

Share Price & News

How has Bellicum Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.9%

BLCM

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-84.6%

BLCM

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: BLCM underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: BLCM underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

BLCMIndustryMarket
7 Day-6.9%1.6%0.4%
30 Day-27.3%-2.4%-1.2%
90 Day-50.0%-1.5%-0.4%
1 Year-84.6%-84.6%-6.9%-7.7%9.3%6.9%
3 Year-95.3%-95.3%14.7%10.7%45.8%36.4%
5 Yearn/a-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is Bellicum Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bellicum Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BLCM ($0.8) is trading below our estimate of fair value ($7.1)

Significantly Undervalued: BLCM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BLCM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BLCM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BLCM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLCM is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Bellicum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

37.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLCM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLCM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLCM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLCM's revenue (68.8% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: BLCM's revenue (68.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BLCM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bellicum Pharmaceuticals performed over the past 5 years?

-13.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BLCM is unprofitable, and losses have increased over the past 5 years at a rate of -13.6% per year.

Accelerating Growth: Unable to compare BLCM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLCM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: BLCM has a negative Return on Equity (-338.15%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BLCM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BLCM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Bellicum Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BLCM's short term assets ($59.1M) exceeds its short term liabilities ($22.1M)

Long Term Liabilities: BLCM's short term assets (59.1M) exceeds its long term liabilities (37.3M)


Debt to Equity History and Analysis

Debt Level: BLCM's debt to equity ratio (119.7%) is considered high

Reducing Debt: BLCM's debt to equity ratio has increased from 6.3% to 119.7% over the past 5 years.


Balance Sheet

Inventory Level: BLCM has a high level of physical assets or inventory.

Debt Coverage by Assets: BLCM's debt is covered by short term assets (assets are 1.629510x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLCM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BLCM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -12% each year


Next Steps

Dividend

What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BLCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLCM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BLCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLCM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLCM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Bellicum Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Rick Fair (50yo)

2.8yrs

Tenure

US$3,278,125

Compensation

Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31 ...


CEO Compensation Analysis

Compensation vs. Market: Rick's total compensation ($USD3.28M) is about average for companies of similar size in the US market ($USD491.38K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.3yrs

Average Tenure

50yo

Average Age

Experienced Management: BLCM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: BLCM's board of directors are considered experienced (3.1 years average tenure).


Insider Trading

Insider Buying: BLCM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$50,00011 Sep 19
Richard Fair
EntityIndividual
Role
Chief Executive Officer
President
Shares40,000
Max PriceUS$1.25
BuyUS$9,82230 Aug 19
Shane Ward
EntityIndividual
Role
Chief Legal Officer
General Counsel & Corporate Secretary
Shares8,000
Max PriceUS$1.23
BuyUS$19,78023 Aug 19
Richard Fair
EntityIndividual
Role
Chief Executive Officer
President
Shares20,000
Max PriceUS$0.99
BuyUS$45,60013 Nov 18
Jon Stonehouse
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$4.56

Ownership Breakdown


Management Team

  • Atabak Mokari (42yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
  • Alan Smith (61yo)

    Executive Vice President of Technical Operations

    • Tenure: 4yrs
    • Compensation: US$1.05m
  • Tom Farrell (56yo)

    Consultant

    • Tenure: 2.8yrs
    • Compensation: US$1.72m
  • Rick Fair (50yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$3.28m
  • Shane Ward (44yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.4yrs
    • Compensation: US$1.15m
  • Aaron Foster

    Head of Research & Senior VP

    • Tenure: 0.6yrs
  • Rosie Williams

    Interim Principal Accounting Officer

    • Tenure: 1.2yrs
  • Joseph Woodard

    Senior Vice President of Clinical & Medical Affairs

    • Tenure: 0.5yrs

Board Members

  • Steve Davis (58yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$124.47k
  • James Brown (54yo)

    Chairman of the Board

    • Tenure: 4.8yrs
    • Compensation: US$145.51k
  • Ed Harrigan (66yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$208.30k
  • Jim Daly (57yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$103.73k
  • Jon Stonehouse (58yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$128.79k
  • David Spencer (57yo)

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.6yrs
  • Rick Fair (50yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$3.28m
  • Reid Huber (47yo)

    Director

    • Tenure: 5yrs
    • Compensation: US$125.66k
  • Judith Klimovsky (61yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$136.99k
  • Malcom Brenner

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.6yrs

Company Information

Bellicum Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bellicum Pharmaceuticals, Inc.
  • Ticker: BLCM
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$37.003m
  • Shares outstanding: 46.25m
  • Website: https://www.bellicum.com

Number of Employees


Location

  • Bellicum Pharmaceuticals, Inc.
  • 2130 West Holcombe Boulevard
  • Suite 800
  • Houston
  • Texas
  • 77030
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLCMNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2014
BPXDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2014
0HMSLSE (London Stock Exchange)YesCommon StockGBUSDDec 2014

Biography

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:44
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.